Association between estimated glucose disposal rate and lower extremity arterial disease in type 2 diabetes: A nationwide cross-sectional study from China.

IF 5.4 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Xiaowei Wei, Jie Zhao, Ping Zhu, Wenfang Niu, Zhangrong Xu, Xingwu Ran, Xiaomei Zhang, Aihong Wang, Linong Ji
{"title":"Association between estimated glucose disposal rate and lower extremity arterial disease in type 2 diabetes: A nationwide cross-sectional study from China.","authors":"Xiaowei Wei, Jie Zhao, Ping Zhu, Wenfang Niu, Zhangrong Xu, Xingwu Ran, Xiaomei Zhang, Aihong Wang, Linong Ji","doi":"10.1111/dom.16514","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Lower extremity arterial disease (LEAD), a prevalent but under-recognised macrovascular complication of type 2 diabetes mellitus (T2DM), is closely linked to insulin resistance (IR). The estimated glucose disposal rate (eGDR), a surrogate marker of IR, may facilitate early LEAD risk stratification; however, its clinical utility remains underexplored.</p><p><strong>Materials and methods: </strong>This cross-sectional analysis of 7482 adults aged ≥50 years with T2DM, from the China DIA-LEAD study evaluated the association between eGDR (quartiles: Q1-Q4) and LEAD, defined by the ankle-brachial index (ABI <0.9 or >1.3). Multivariate logistic regression and restricted cubic spline (RCS) models were used to assess the nonlinear relationships, adjusted for demographics, metabolic factors and comorbidities.</p><p><strong>Results: </strong>Participants in the lower eGDR quartiles showed a progressively higher LEAD prevalence (Q1: 31.4% vs. Q4: 12.8%), worse glycaemic control (HbA1c Q1: 9.8% vs. Q4: 7.3%) and a greater comorbidity burden (all p < 0.001). In fully adjusted models, Q1 had a 2.23-fold higher LEAD risk versus Q4 (95% CI 1.47-3.37). Each 1-unit eGDR increase conferred a 24% lower LEAD risk (adjusted OR 0.76, 95% CI 0.70-0.84). RCS analysis revealed an L-shaped relationship, with sharp risk escalation at eGDR < 8 mg/kg/min (p for nonlinearity = 0.003). Subgroup analyses confirmed consistency across populations (all p for interaction >0.05).</p><p><strong>Conclusions: </strong>eGDR demonstrated a significant inverse L-shaped association with LEAD in patients with T2DM. These findings support the clinical utility of eGDR as a practical indicator of LEAD risk screening and management. Patients with lower eGDR may benefit from insulin-sensitising therapies, which could reduce both glucose levels and the risk of LEAD.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16514","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Lower extremity arterial disease (LEAD), a prevalent but under-recognised macrovascular complication of type 2 diabetes mellitus (T2DM), is closely linked to insulin resistance (IR). The estimated glucose disposal rate (eGDR), a surrogate marker of IR, may facilitate early LEAD risk stratification; however, its clinical utility remains underexplored.

Materials and methods: This cross-sectional analysis of 7482 adults aged ≥50 years with T2DM, from the China DIA-LEAD study evaluated the association between eGDR (quartiles: Q1-Q4) and LEAD, defined by the ankle-brachial index (ABI <0.9 or >1.3). Multivariate logistic regression and restricted cubic spline (RCS) models were used to assess the nonlinear relationships, adjusted for demographics, metabolic factors and comorbidities.

Results: Participants in the lower eGDR quartiles showed a progressively higher LEAD prevalence (Q1: 31.4% vs. Q4: 12.8%), worse glycaemic control (HbA1c Q1: 9.8% vs. Q4: 7.3%) and a greater comorbidity burden (all p < 0.001). In fully adjusted models, Q1 had a 2.23-fold higher LEAD risk versus Q4 (95% CI 1.47-3.37). Each 1-unit eGDR increase conferred a 24% lower LEAD risk (adjusted OR 0.76, 95% CI 0.70-0.84). RCS analysis revealed an L-shaped relationship, with sharp risk escalation at eGDR < 8 mg/kg/min (p for nonlinearity = 0.003). Subgroup analyses confirmed consistency across populations (all p for interaction >0.05).

Conclusions: eGDR demonstrated a significant inverse L-shaped association with LEAD in patients with T2DM. These findings support the clinical utility of eGDR as a practical indicator of LEAD risk screening and management. Patients with lower eGDR may benefit from insulin-sensitising therapies, which could reduce both glucose levels and the risk of LEAD.

2型糖尿病患者葡萄糖处理速率与下肢动脉疾病之间的关系:一项来自中国的全国性横断面研究
目的:下肢动脉疾病(LEAD)是2型糖尿病(T2DM)的一种普遍但未被充分认识的大血管并发症,与胰岛素抵抗(IR)密切相关。估计的葡萄糖处置率(eGDR)是IR的替代标志物,可能有助于早期的铅风险分层;然而,其临床应用仍未得到充分探索。材料和方法:这项来自中国DIA-LEAD研究的7482名年龄≥50岁的T2DM成年人的横断面分析评估了eGDR(四分位数:Q1-Q4)和LEAD之间的关系,由踝臂指数(ABI 1.3)定义。采用多变量logistic回归和限制性三次样条(RCS)模型评估非线性关系,并根据人口统计学、代谢因素和合并症进行调整。结果:eGDR四分位数较低的参与者显示出逐渐升高的铅患病率(Q1: 31.4% vs. Q4: 12.8%),更差的血糖控制(HbA1c Q1: 9.8% vs. Q4: 7.3%)和更大的合病负担(均p 0.05)。结论:T2DM患者的eGDR与铅呈显著的负l型相关。这些发现支持eGDR作为铅风险筛查和管理的实用指标的临床应用。eGDR较低的患者可能受益于胰岛素增敏治疗,这可以降低血糖水平和铅的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信